《眼内结核诊断规范》团体标准解读

doi:10.19982/j.issn.1000-6621.20240572

中国防痨杂志 ›› 2025, Vol. 47 ›› Issue (3): 258-261.doi: 10.19982/j.issn.1000-6621.20240572

《眼内结核诊断规范》团体标准解读

段鸿飞¹, 陶勇²()

¹首都医科大学附属北京胸科医院结核科,北京 101149
²首都医科大学附属北京朝阳医院眼科,北京 100020

收稿日期:2024-12-17 出版日期:2025-03-10 发布日期:2025-02-27
通信作者: 陶勇,Email:taoyong@mail.ccmu.edu.cn
基金资助:
北京市高层次公共卫生人才项目(Discipline Leader-03-008);国家自然科学基金面上项目(82471081);北京市医院管理中心“登峰”计划(DFL20220301);首都卫生发展科研专项(2022-2-2035);首都医学科学创新中心优秀青年人才创新项目(CX23YQA02)

Interpretation of social organization standard of Diagnosis Specification of Intraocular Tuberculosis

Duan Hongfei¹, Tao Yong²()

¹Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
²Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

Received:2024-12-17 Online:2025-03-10 Published:2025-02-27
Contact: Tao Yong, Email: taoyong@mail.ccmu.edu.cn
Supported by:
Beijing High-Level Public Health Talent Program(Discipline Leader-03-008);National Natural Science Foundation of China(82471081);Beijing Hospitals Authority’s Ascent(DFL20220301);Capital Health Development Research Special Project(2022-2-2035);Excellent Young Talent Innovation Project from the Chinese Institutes for Medical Research(CX23YQA02)

摘要/Abstract

摘要：

2024年10月17日,《T/CHATA 045—2024眼内结核诊断规范》团体标准正式发布并于当日开始实施。本文就该标准核心要点进行解读,旨在帮助全国各级医疗机构相关医务人员掌握眼内结核的诊断要点,提高诊断同质化水平,减少误诊、漏诊,规范诊断。

关键词: 结核,眼, 诊断,鉴别, 规范, 评论

Abstract:

On October 17, 2024, the social organization standard Diagnosis Specification of Intraocular Tuberculosis (T/CHATA 045—2024) was officially released and implemented on the same day. This article interprets the core points of the standard, aiming to help medical personnel at all levels of healthcare institutions across the country grasp the key points of intraocular tuberculosis diagnosis, improve the standardization of diagnosis, reduce misdiagnosis and missed diagnosis, and regulate diagnosis.

Key words: Tuberculosis, ocular, Diagnosis, differential, Benchmarking, Comment

中图分类号:

R52
R771

段鸿飞, 陶勇. 《眼内结核诊断规范》团体标准解读[J]. 中国防痨杂志, 2025, 47(3): 258-261. doi: 10.19982/j.issn.1000-6621.20240572

Duan Hongfei, Tao Yong. Interpretation of social organization standard of Diagnosis Specification of Intraocular Tuberculosis[J]. Chinese Journal of Antituberculosis, 2025, 47(3): 258-261. doi: 10.19982/j.issn.1000-6621.20240572

参考文献 8

[1]	World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
[2]	Agrawal R, Gunasekeran DV, Grant R, et al. Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1. JAMA Ophthalmol, 2017, 135(12): 1318-1327. doi:10.1001/jamaophthalmol.2017.4485. pmid: 29075752
[3]	Dalvin LA, Smith WM. Intraocular manifestations of Mycobacterium tuberculosis: A review of the literature. J Clin Tuberc Other Mycobact Dis, 2017, 7: 13-21. doi:10.1016/j.jctube.2017.01.003.
[4]	Gupta A, Sharma A, Bansal R, et al. Classification of intraocular tuberculosis. Ocul Immunol Inflamm, 2015, 23(1): 7-13. doi:10.3109/09273948.2014.967358. pmid: 25314361
[5]	Xie J, Qu Y, Qian Z, et al. Clinical manifestation and long-term follow-up of presumed ocular tuberculosis in China. J Clin Tuberc Other Mycobact Dis, 2023, 34: 100413. doi:10.1016/j.jctube.2023.100413.
[6]	Agrawal R, Betzler BK, Testi I, et al. The Collaborative Ocular Tuberculosis Study (COTS) -1: A Multinational Review of 447 Patients with Tubercular Intermediate Uveitis and Panuveitis. Ocul Immunol Inflamm, 2020, 28(sup1): 27-37. doi:10.1080/09273948.2020.1808226.
[7]	Agrawal R, Testi I, Bodaghi B, et al. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis-Report 2: Guidelines for Initiating Antitubercular Therapy in Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Retinal Vasculitis. Ophthalmology, 2021, 128(2): 277-287. doi:10.1016/j.ophtha.2020.06.052. pmid: 32603726
[8]	Jiang T, Zhang X, Zhou M, et al. Prognosis of Ocular Tuberculosis Following Long-Term Antitubercular Therapy. J Ocul Pharmacol Ther, 2021, 37(4): 241-247. doi:10.1089/jop.2020.0100. pmid: 33524301

[1]	赵艳丽, 车南颖. 《结核病病理学诊断规范》团体标准解读[J]. 中国防痨杂志, 2024, 46(4): 371-374.
[2]	邓国防, 王庆文. 重视风湿性疾病合并结核感染的多学科诊治[J]. 中国防痨杂志, 2022, 44(9): 865-868.
[3]	安慧茹, 吴雪琼. 《活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版)》的免疫辅助治疗解读[J]. 中国防痨杂志, 2022, 44(6): 539-543.
[4]	安慧茹, 吴雪琼. 结核病免疫辅助治疗现状与挑战[J]. 中国防痨杂志, 2022, 44(10): 983-986.
[5]	李仁忠, 阮云洲, 李玉红. 关于世界卫生组织广泛耐药结核病新定义的解读[J]. 中国防痨杂志, 2021, 43(6): 539-541.
[6]	刘二勇, 李玉红, 周林, 赵雁林. 统筹兼顾:肺外结核应纳入防治规划[J]. 中国防痨杂志, 2021, 43(5): 428-431.
[7]	邓国防. 《结核病与糖尿病共病的治疗管理专家共识》解读[J]. 中国防痨杂志, 2021, 43(4): 318-321.
[8]	冯莹, 任斐. 2019年南非《利福平耐药结核病管理临床指南》解读及与我国《耐药结核病化学治疗指南(2019年)》对比[J]. 中国防痨杂志, 2021, 43(3): 295-298.
[9]	贺晓新, 李波, 周林. 《4个月含利福喷丁抗结核治疗方案疗效观察》解读[J]. 中国防痨杂志, 2021, 43(12): 1243-1247.
[10]	杨春龙, 周林, 陈明亭. 《病原学检测阴性肺结核诊断流程(T/CHATA 008—2020)》解读[J]. 中国防痨杂志, 2021, 43(11): 1116-1119.
[11]	靳鸿建. 我国县级结核病防治服务体系建设及防治工作亟需加强——一位老防痨工作者的意见和建议[J]. 中国防痨杂志, 2020, 42(9): 896-902.
[12]	张灿有, 夏辉, 成君. Ⅱ级生物安全柜在结核病实验室中的检测及报告要求[J]. 中国防痨杂志, 2020, 42(9): 903-909.
[13]	成君. 《新生入学体检结核病检查规范》解读[J]. 中国防痨杂志, 2020, 42(9): 987-989.
[14]	沈鑫, 肖筱, 白丽琼, 潘启超. 《学校肺结核患者密切接触者筛查及处置规范》解读[J]. 中国防痨杂志, 2020, 42(9): 990-991.
[15]	李涛, 杜昕, 陈伟, 黄飞, 赵雁林, 张慧. 中国结核病管理信息监测与监控的回顾与展望[J]. 中国防痨杂志, 2020, 42(7): 657-661.

《眼内结核诊断规范》团体标准解读

Interpretation of social organization standard of Diagnosis Specification of Intraocular Tuberculosis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 8

相关文章 15

编辑推荐

Metrics

本文评价

友情链接